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The long-chain omega-3 polyunsaturated fatty acids (n-3 
PUFAs)—eicosapentaenoic acid (EPA) and its metabolite doco-
sahexaenoic acid (DHA)—inhibit cancer formation in vivo, but 
their mechanism of action is unclear. Extracellular signal-reg-
ulated kinase 1/2 (ERK1/2) activation and inhibition have both 
been associated with the induction of tumour cell apoptosis by n-3 
PUFAs. We show here that low doses of EPA, in particular, inhib-
ited the growth of premalignant and malignant keratinocytes 
more than the growth of normal counterparts by a combination of 
cell cycle arrest and apoptosis. The growth inhibition of the oral 
squamous cell carcinoma (SCC) lines, but not normal keratino-
cytes, by both n-3 PUFAs was associated with epidermal growth 
factor receptor (EGFR) autophosphorylation, a sustained phos-
phorylation of ERK1/2 and its downstream target p90RSK but 
not with phosphorylation of the PI3 kinase target Akt. Inhibition 
of EGFR with either the EGFR kinase inhibitor AG1478 or an 
EGFR-blocking antibody inhibited ERK1/2 phosphorylation, 
and the blocking antibody partially antagonized growth inhi-
bition by EPA but not by DHA. DHA generated more reactive 
oxygen species and activated more c-jun N-terminal kinase than 
EPA, potentially explaining its increased toxicity to normal 
keratinocytes. Our results show that, in part, EPA specifically 
inhibits SCC growth and development by creating a sustained sig-
nalling imbalance to amplify the EGFR/ERK/p90RSK pathway 
in neoplastic keratinocytes to a supraoptimal level, supporting the 
chemopreventive potential of EPA, whose toxicity to normal cells 
might be reduced further by blocking its metabolism to DHA. 
Furthermore, ERK1/2 phosphorylation may have potential as a 
biomarker of n-3 PUFA function in vivo.
Introduction
Oral squamous cell carcinomas (SCCs) are the sixth most common 
cancers worldwide (1). SCCs of the aerodigestive tract account 
for ~10% of the malignancies in the developed world and are 
very expensive to treat (2), so there is a strong health economic 
argument for reducing the number of advanced cases, particularly 
in risk groups, such as former smokers. A  major problem is that 
these SCCs arise from a generalized field of abnormal mucosa that 
can evolve in widely separated areas of the aerodigestive tract. 
Second field or second primary cancers are a common cause of 
relapse (3,4), suggesting that cost-effective chemopreventive strat-
egies could be a novel adjunct to conventional therapies. Several 
studies suggest that the long-chain omega-3 polyunsaturated fatty 
acids (n-3 PUFAs)—eicosapentaenoic acid (EPA) and docosahex-
aenoic acid (DHA)—have significant chemopreventive and thera-
peutic potential against cancer (reviewed in ref. 5). Dietary intake 
of n-3 PUFAs is associated with a lower risk of several cancers, 
including SCC (6), and inhibits both the growth (7) and metastasis 
(8) of animal tumours and xenografts (8). Topically applied EPA 
also inhibits both the initiation and promotion phases of mouse epi-
dermal tumorigenesis without affecting cell proliferation (9). The 
fat-1 transgenic mouse, which produces a higher level of n-3 fatty 
acids endogenously, is resistant to several types of cancer (10–12). 
The beneficial effects of n-3 PUFAs in the treatment and prevention 
of cancer may involve a multitude of mechanisms, but the accessi-
bility of aerodigestive tract and epidermal SCCs to therapeutic aer-
osols or gels makes it an attractive model to test the therapeutic and 
prophylactic potential of n-3 PUFAs. The safety and tolerability of 
these compounds have already been documented in other clinical 
indications (13). However, the effects of n-3 PUFAs on malignant 
cells and their premalignant or normal counterparts have not been 
compared previously.
There is considerable evidence that both DHA and EPA can 
induce apoptosis in several cancer cell lines (14,15) but whether this 
is the full explanation for their anticancer activity is not clear, and 
there is little consensus on their molecular mechanism of action, 
which appears to be pleiotropic. Some studies link the tumour-
suppressive action of n-3 PUFAs with the mitogen-activated protein 
kinase pathway and either the activation or inactivation of its com-
ponents with the induction of apoptosis (16,17) and growth arrest 
(18,19), suggesting that there may be tissue- or cancer-specific 
mechanisms of n-3 PUFAs action. In particular, as regards extra-
cellular signal-regulated kinase 1/2 (ERK1/2), some studies showed 
that n-3 PUFAs promote apoptosis in cancer cells by reducing the 
levels of p-ERK1/2 (20–23). Traditionally, the activation of ERK1/2 
is linked to cell survival and proliferation (24). However, recent 
studies demonstrated that this is not always the case, and activation 
of ERK could actually cause apoptosis or growth arrest (25–28). At 
higher doses, n-3 PUFAs have been reported to induce the produc-
tion of reactive oxygen species (ROS) (29) and c-jun N-terminal 
kinase (JNK) phosphorylation and induce apoptosis (30) or growth 
arrest (19).
We report here that both DHA and EPA induce apoptosis and 
growth arrest in human normal and neoplastic keratinocytes from 
the epidermis and oral cavity. However, in particular, EPA, at a 
lower dose, inhibited the growth of premalignant and malignant 
keratinocytes more than the growth of normal keratinocytes, 
whereas DHA was less selective. The growth inhibition at the 
selective low doses of EPA required occupancy of the epidermal 
growth factor receptor (EGFR) and was associated with a sus-
tained activation of ERK1/2, which did not occur in non-neoplastic 
keratinocytes at the same dose. PI3 kinase was not activated in 
parallel. Therefore, our results suggest that n-3 PUFAs may exert 
some of their anticancer effects by inducing over-stimulation of 
ERK1/2 or a signalling imbalance downstream of the EGFR path-
way. Our results also suggest that n-3 PUFAs or their derivatives 
may have potential in the prevention or reduction of aerodigestive 
tract and epidermal SCC.
Abbreviations: ANOVA, analysis of variance; DCF, 2′,7′-dichlorodihydrofluo-
rescein diacetate; DHA, docosahexaenoic acid; EGFR, epidermal growth factor 
receptor; EPA, eicosapentaenoic acid; ERK 1/2, extracellular signal-regulated 
kinase 1/2; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; JNK, c-jun 
N-terminal kinase; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide; p90RSK, p90 ribosomal S6 kinases; PBN, n-tert-butyl-α-phenylnitrone; 
PUFA, polyunsaturated fatty acid; ROS, reactive oxygen species; SCC, squamous 
cell carcinoma; TBS-T, Tris-Buffered Saline and Tween 20.
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Materials and methods
Cell lines
SCC-13 and SCC-25 are tumorigenic keratinocyte lines—epidermal (facial 
epidermis) and oral (tongue), respectively (31)—and SVHFK is an origin of 
replication-defective SV40 mutant virus-transformed epidermal keratinocyte 
line that is not tumorigenic at early passage but becomes so after extensive pas-
saging (32); it can, thus, be considered premalignant. NHEK-131 (Invitrogen, 
Paisley, UK) and HEK-127 are normal foreskin epidermal keratinocyte lines. 
The five cell lines were maintained in keratinocyte basic medium (Cambrex-
Lonza, Walkersville, MD) supplemented with bovine pituitary extract 
(0.03 mg/ml), human EGF (0.1 ng/ml), insulin (5.0 g/ml), hydrocortisone 
(0.5 g/ml) and antibiotics/antimycotics GA-1000 (gentamicin at 50 g/ml and 
amphotericin B at 50 ng/ml) to make keratinocyte growth medium. Two oral 
normal NHOK-810 and NHOK-881, two non-neoplastic immortal OKF6/
TERT-1 (33) and OKF4/cdk4R/p53DD/TERT (34) and three oral dysplasia 
cell lines D17, D19 and D20 (35) were maintained in keratinocyte-SFM (1×) 
medium supplemented with human recombinant 0.2 ng/ml EGF 1–53 and 25 
µg/ml bovine pituitary extract (Invitrogen), 10 µg/ml penicillin and strepto-
mycin (Cambrex-Lonza) and 0.4 mM calcium chloride (33). Cells were main-
tained in a humidified atmosphere of 5% CO2/95% air (epidermal) and 10% 
CO2/90% air (oral) at 37°C.
The cells were disaggregated with 0.1% trypsin (Worthington, Lakewood, 
NJ)/0.01% ethylenediaminetetraacetic acid (Sigma–Aldrich, Gillingham, UK) 
in phosphate-buffered saline when they reached ~50% confluence.
Chemicals
5-8-11-14-17 EPA and 4-7-10-13-16-19 DHA (NU-CHEK, Elysian, MN) 
were purchased as free fatty acids in the form of pure oil and were diluted in 
ethanol under nitrogen at a stock concentration of 0.5 M. The stock was ali-
quoted in dark-coloured glass vials with screw tops (Agilent Technologies, 
Wokingham, UK) to protect from light and oxidation and stored at −20°C 
for up to 6 months. The antioxidant n-tert-butyl-α-phenylnitrone (PBN) 
was obtained from Sigma (Poole Dorset, UK) and added to the growth 
medium to give final concentrations between 50 and 1 mM. The caspase 
inhibitor Q-VD-OPh was from Calbiochem (La Jolla, CA). The MEK 
inhibitor U0126 was from Cell Signaling Technology (Danvers, MA) (data 
not shown) and AZD6244 was from Selech Chemicals (Houston, TX). The 
EGF receptor inhibitor AG1478 was from Invitrogen. The EGFR-blocking 
antibody [EGFR Mouse anti-Human Monoclonal (Azide-free) (225) Ab] 
was from LifeSpan Biosciences (Seattle, WA). The inhibitors were added 
in the culture for 1.5 h and the blocking antibody for 4 h before the addition 
of EPA and DHA. After 2 h since the n-3 PUFAs were added, the lysates 
were obtained.
MTT assay
The cell viability was determined using a colorimetric 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Sigma). The cells were 
seeded at 24-well plates and treated. Medium was replaced with 1 ml serum-
free medium containing 0.5 mg/ml MTT solution and incubated for 1 h, then 
the MTT solution was removed, and 0.5 or 1 ml of dimethyl sulphoxide was 
added to dissolve the formazan dye. Triplicates of 200 µl aliquots from each 
well were transferred to a 96-well plate, and absorbance was read at 540 nm 
using a plate reader.
Annexin-V apoptosis assay
Cells were trypsinized combined with any cells in suspension and pelleted. 
The resuspended cells were then incubated at room temperature for 15 min in 
500 µl of Annexin-V Binding Buffer (Becton Dickinson, Oxford, UK) contain-
ing 4 µl/ml of Annexin-V-FLUOS (Roche Diagnostics Ltd, Burgess Hill, UK) 
and 200 ng/ml of 4′,6-diamidino-2-phenylindole (DAPI) viability dye (Sigma). 
The samples were analysed on a flow cytometer (LSR II BD Biosciences) col-
lecting 10–20 000 events.
3H-Thymidine incorporation assay
Cell proliferation was measured by incorporation of tritiated thymidine 
(3H-TdR). Cells were seeded at 4 × 102 cells/ml/well into sterile 96-well 
flat-bottom tissue culture plates (Fisher Scientific, Edmonton, Alberta, 
Canada) and treated with 3 µM of EPA and DHA, as described for the MTT 
assay. Cell cultures were pulsed with 0.5 µCi/well of 3H-TdR (Amersham, 
UK) and incubated for 18 h. Cells were then harvested onto filters (Wallac 
Perkin Elmer) using a 96-well cell harvester (TOMTEC Harvester 96/Mach 
3M). Scintillation fluid (Wallac) was added to the filter before detection of 
radioactive energy on a beta counter (Wallac). The results of the incorpo-
rated thymidine, in triplicate, were expressed in counts per minute. Counts 
per minute were then expressed as a percentage of the PUFA-untreated 
control.
Preparation of lysates and western blotting
Cells were washed twice in phosphate-buffered saline at 4°C and lysed in radi-
oimmunoprecipitation assay lysis buffer (1% NP-40, 0.1% sodium dodecyl 
sulphate, 50 mM Tris, pH 7.3 and 150 mM NaCl) (all from Sigma) and pro-
tease (cOmplete cocktail tablets) and phosphatase (PhosSTOP cocktail tablets) 
inhibitors (both from Roche Diagnostics) for 20 min on ice and centrifuged 
at 15 000 r.p.m. for 20 min at 4°C. Supernatant protein concentrations were 
determined by the DC protein assay (Bio-Rad, Hemel Hempstead, UK), and 
10–35 µg of protein was boiled for 5 min at 100°C in sodium dodecyl sulphate 
sample buffer (5×, 0.3 M Tris–HCl, pH 6.8, 10% sodium dodecyl sulphate, 
50% glycerol, 20% 2-mercaptoethanol, 0.25% bromophenol blue; all from 
Sigma) before storage at −80°C.
Lysates were run on 4–12% NuPAGE Novex Bis-Tris gels under denatur-
ing and reducing conditions (Invitrogen) at 130 V and transferred to 0.45 µm 
Immobilon PVDF membranes (Millipore, Watford, UK) by a wet transfer 
system (Invitrogen). Membranes were blocked in 5% low fat milk (Marvel, 
Bristol, UK) in Tris-Buffered Saline and Tween 20 (TBS-T) (1 M Tris, pH 
8.0, 5 M NaCl and 0.05% Tween 20) (all from Sigma) for 1 h. Primary anti-
body was added in 5% milk in TBS-T or 5% bovine serum albumin (PAA, 
Pasching, Austria) in TBS-T, according to the antibodies manufacturer’s 
instructions, incubated overnight at 4°C and then washed with TBS-T. The 
membrane was incubated in appropriate horseradish peroxidase-conjugated 
secondary antibody in 5% milk in TBS-T at room temperature for 1 h and 
then washed again with TBS-T and then visualized by chemiluminescence 
(Amersham ECL Plus) on Amersham Hyperfilm ECL (both from GE 
Healthcare Life Sciences).
Antibodies
Cleaved caspase 3, cleaved caspase 8, cleaved caspase 9 (Asp330), caspase 
8, caspase 9, phospho-p44/42 MEK (Thr202/Tyr204) (phospho-ERK1/2), 
total AKT, phospho-p90RSK (rabbit polyclonals; Cell Signaling), anti-
Akt/PKB[pS473] (rabbit polyclonal; Biosource-Invitrogen) and caspase 
3 (goat polyclonal from R&D systems) were all used at 1:1000 dilution. 
P44/42 MEK (ERK1/2) (mouse monoclonal; Cell Signaling) was used at 
1:2000. RSK1/2/3 and EGFR (both from Cell Signaling) and phospho-
EGFR (BD Transduction Laboratories) antibodies were used at 1:1000 and 
1:500, respectively. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
mouse monoclonal and α-tubulin rabbit polyclonal antibodies (both from 
Abcam) were used at 1:5000 and 1:2000, respectively. Secondary antibod-
ies were horseradish peroxidase-conjugated anti-rabbit and anti-mouse IgG 
goat polyclonal antibodies (Pierce, Thermo-Scientific) and an anti-goat IgG 
mouse monoclonal antibody (Sigma) used at 1:2500, 1:3000 and 1:10 000, 
respectively.
Detection of ROS and oxidative damage and antioxidant treatment
The 2′,7′-dichlorodihydrofluorescein diacetate (Calbiochem-Merck, 
Nottin gham, UK) cell-permeable fluorogenic probe, that detects the ROS 
and NO, was used to determine the overall oxidative stress in the cells. 
Moreover, dihydroethidium (Invitrogen), which is a superoxide indica-
tor, was used to confirm oxidation (data not shown). After the cells were 
treated with DHA and EPA for 16 h, they were incubated with 1 µM of 
2′,7′-dichlorodihydrofluorescein diacetate (DCF) or 5 µM of dihydroeth-
idium and 250 ng/ml of DAPI for 30 min in 37°C. The fluorescent inten-
sity of the dye uptake was measured by a flow cytometer (LSR II BD 
Biosciences), collecting 10–20  000 events. The HFF cell line, which is 
a human fetal skin fibroblast cell line with low ROS levels, was used as 
negative control, whereas cells treated with 100 µM of tert-butyl hydrop-
eroxide (which causes oxidative damage), for just 2 h at 37°C, were used 
as positive controls.
The 8-hydroxy-2′-deoxyguanosine antibody (anti-8-oxo-dG, Clone 2E2) 
from Trevigen (Gaithersburg, MD) was used to detect oxidative damage by 
immunocytochemistry according to the supplier’s protocol. The cells were 
treated with DHA and EPA for 16 h. Cells treated with 100 µM tert-butyl 
hydroperoxide at 37°C for 2 h were used as positive controls. The cells were 
visualized with a Leica DM5000 epifluorescence microscope under the ×40 
objective lens and ×100 oil emersion lens and analysed with the Metamorph 
Imaging Software (Sunnyvale, CA).
SCC-25 cells were treated with the antioxidants PBN 600 and 800 µM or 
α-tocopherol (40 µM) (both from Sigma) before the addition of the n-3 PUFAs 
and the MTT assay. PBN was shown to reduce oxidation at the concentrations 
used (36).
Statistical analysis
The non-parametric Wilcoxon Mann–Whitney Rank test and the one-way 
analysis of variance (ANOVA) followed by post hoc Bonferroni test were used 
and performed via the SPSS statistical software (version 17; Chicago, IL). A P 
value <0.05 was considered significant.
2717
Z.Nikolakopoulou et al.
Results
The n-3 PUFAs, EPA and DHA selectively inhibit the growth of pre-
malignant and malignant keratinocytes compared with their normal 
or immortalized counterparts
Figure 1 shows that both DHA and EPA inhibit the growth of prema-
lignant and malignant keratinocytes more than their normal or immor-
talized counterparts, as assessed by the MTT assay. EPA was far 
more selective than DHA causing 2.5-fold (premalignant) to 3.5-fold 
(malignant) more growth inhibition than in their normal counterparts 
at a dose of 3 µM and 4-fold (malignant) to 6-fold (premalignant) 
at 5 µM (a highly significant difference), as compared with DHA, 
which caused only 1.5-fold (premalignant: not significant) to 2-fold 
(malignant) more growth inhibition at a dose of 3 µM. DHA was 
not selective at 5 µM (Figure 1d). In the epidermal lines studied, the 
SV40-transformed line SVHFK, which has premalignant properties 
(32), was more sensitive than the SCC line, SCC-13 and both were 
more sensitive than the two normal epidermal lines NHEK-131 and 
HEK-127 (Figure 1a–c and f). All three oral dysplastic lines (35) were 
less sensitive than their malignant counterpart SCC-25 at 3 µM but 
more sensitive than the two normal oral keratinocyte lines tested and 
also more sensitive than two normal oral keratinocyte lines immortal-
ized by telomerase (Figure 1a and b).
The increased sensitivity of the neoplastic keratinocytes lines is 
independent of immortalization, telomerase activation and p53 
and/or p16INK4A inactivation
Normal oral keratinocytes lines immortalized by ectopic telomerase 
expression (OKF6/TERT-1 and OKF4/cdk4R/p53DD/TERT) were 
more resistant to n-3 PUFAs growth inhibition than normal keratino-
cytes (Figure 1a–c). Previous studies have shown that OKF6/TERT-1 
line also has reduced p16INK4A (33), and OKF4/cdk4R/p53DD/TERT 
additionally has inactivated p53 and p16INK4A (34). In contrast, although 
the premalignant SVHFK line would also have inactive p53 and pRb/
p16INK4A pathways owing to the presence of SV40 large T antigen and 
expresses telomerase, it would additionally harbour the oncogenic 
effects of the small T antigen (32) and was hypersensitive to both n-3 
PUFAs, as was the mortal dysplastic D17 line. These observations sug-
gest that as yet uncharacterized oncogenic mutations in the dysplastic 
and SCC lines, and not the events leading to immortalization, such as 
p16INK4A/p53/telomerase dysfunction, are connected with the increased 
sensitivity of these neoplastic keratinocytes to the n-3 PUFAs.
Fig. 1. The effect of n-3 PUFAs on the growth of normal, premalignant and malignant keratinocytes. The growth of the keratinocytes was measured by the MTT 
viability assay 4 days after the addition of the n-3 PUFAs at the indicated doses. The effect of 3 µM EPA (a), 5 µM EPA (b), 3 µM DHA (c) and 5 µM DHA 
(d) on the growth of the malignant (black), premalignant (hatched), normal (white) and immortal normal (grey bars) keratinocytes is shown, as determined by 
the MTT assay. The results are the means of three or more experiments ± standard error of the mean (SEM). (e) An overview of the means ± SEM of the MTT 
assay for the malignant (black), premalignant (hatched) and normal keratinocytes (white) averages. The overview for the epidermal keratinocytes (f) and the oral 
keratinocytes (g) is shown, where the immortal normal oral lines are included (grey bars). Significantly different from the mean value of normal keratinocytes 
(*P < 0.05; **P < 0.01; ***P < 0.001 as measured by the Mann–Whitney U-rank test). The malignant cells include SCC-25 (oral) and SCC-13 (epidermal). The 
premalignant cells include the three oral dysplasias (D17, D19 and D20) and the epidermal SVHFK. The normal cells include the normal oral lines (NHOK-810 
and NHOK-881), the epidermal lines (HEK-127 and NHEK-131) and the immortal normal oral lines OKF6/TERT-1 and OKF4/cdk4R/p53DD/TERT.
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Growth inhibition by n-3 PUFAs in keratinocytes is mediated by 
both apoptosis and cell cycle arrest
n-3 PUFAs have been reported to inhibit both cell proliferation (19) 
and induce apoptosis (17) to reduce viable cell number. Therefore, 
we investigated the basis for the inhibition of SCC-25 growth 
in more detail as it was the cell line, which showed the greatest 
response to n-3 PUFA-induced growth inhibition. The detection of 
Annexin-V, which recognizes translocated phosphatidylserine (37), 
was used to detect early apoptotic cells, and the simultaneous appli-
cation of the DNA stain DAPI allowed the discrimination of the 
necrotic cells from the Annexin-V-positive cells. Supplementary 
Figure  1, available at Carcinogenesis Online, shows representa-
tive fluorescence-activated cell sorting data showing the reduced 
viability from 93% in the control to 14% after 5 µM DHA and 41% 
after 5 µM EPA. In general, DHA resulted in a higher percentage 
of late apoptotic cells (Figure 2a) than EPA (Figure 2b) after 48 h 
of treatment and caused a greater induction of total apoptosis in 
normal keratinocytes (3-fold versus 2-fold) at a dose of 5 µM. DHA 
induced apoptosis in the neoplastic cells by 4- to 9-fold and EPA by 
4- to 7-fold at the same dose.
To confirm that the dead cells were indeed apoptotic, we sub-
jected the n-3 PUFA-treated SCC-25 cells to western blot analy-
sis and tested for the cleavage of three caspases known to mediate 
apoptosis. Lysates were obtained for different time points of incuba-
tion with DHA and EPA between 30 min and 24 h. Figure 2c shows 
that both caspase 8 and caspase 9, in addition to the executioner cas-
pase 3, were cleaved within 5 h of DHA treatment and within 17 h 
of EPA treatment. These data support the hypothesis that n-3 PUFAs 
were causing growth inhibition in part by inducing apoptosis, and 
the activation of caspase 8, in addition to caspase 9, suggests that 
both the extrinsic and the mitochondrial apoptotic pathways were 
involved (38).
In addition, we used a 3H-thymidine incorporation assay to test 
whether n-3 PUFAs were also capable of inhibiting SCC-25 prolifera-
tion, and Figure 2d shows that this was indeed the case with DHA-
treated cells showing virtually no incorporation and EPA-treated cells 
showing >75% reduction.
n-3 PUFAs activate the EGFR in SCC but not in non-neoplastic 
keratinocytes
Figure 3a shows that both DHA and EPA induce autophosphoryl-
ation and activation of the EGFR in SCC-25 after 2 h. However, 
EGFR phosphorylated levels were considerably lower in the immor-
tal non-neoplastic OKF6/TERT-1 keratinocytes, which has much 
lower endogenous levels of EGFR, and in fact EGFR activation is 
decreased by EPA and to a lesser extent, by DHA. The increased 
Fig. 2. n-3 PUFAs inhibit growth by inducing apoptosis and inhibiting cell proliferation. Annexin-V assays showing the effect of (a) DHA and (b) EPA on 
apoptosis  48 h after adding doses of 5 and 10 µM to normal (HEK27), premalignant (SVHFK) and malignant (SCC-13 and SCC-25) keratinocytes. Early 
apoptotic cells are indicated by the black part of the bar, and the late apoptotic and necrotic cells (Annexin-V +ve/DAPI +ve) by the white part of the bar. 
The results in (a) and (b) are the means of three experiments ± SEM. Significantly different from the mean value of normal keratinocytes [*P < 0.05; **P < 
0.01; ***P < 0.001 as measured by one-way ANOVA followed by post hoc Bonferroni test]. (c) Western blot analysis of caspases 3, 8 and 9 in SCC-25 cells 
treated for 5 h with DHA and 17 h with EPA 10 µM compared with the ethanol vehicle control. C = cleaved caspase; T = total caspase; GAPDH is the loading 
control. The positive control was an extract from normal keratinocytes NHEK treated with cisplatin for 24 h. The blots are representative of three independent 
experiments. (d) 3H-thymidine incorporation assay performed on SCC-25 cells treated with a dose of 3 µM DHA (white bars) and EPA (hatched bars) for 48 h 
compared with the vehicle control (black bars). The results are the means of six independent experiments ± SEM. SCC-25 cells were incubated in 3 µM DHA 
and EPA for 48 h in keratinocyte growth medium serum-free medium and 3H-thymidine was added 18 h prior to the incorporated thymidine measurement. The 
values were normalized to a percentage of the untreated control, which was taken as 100%. Significantly different from the mean value of the untreated control 
(***P < 0.001 as measured by one-way ANOVA followed by post hoc Bonferroni test).
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activation of EGFR in SCC-25 relative to the non-neoplastic OKF6/
TERT-1 keratinocytes suggested that activation of EGFR could be 
linked to the selective growth inhibition of the former, as high doses 
of EGF that are beneficial to normal keratinocytes inhibit SCC 
keratinocytes (39), and sustained ERK1/2 phosphorylation down-
stream is associated with growth inhibition (40). Therefore, we 
investigated whether ERK1/2 was differentially phosphorylated in 
SCC cells.
n-3 PUFAs increase ERK1/2 phosphorylation and activation in 
SCC but do not activate Akt
ERK1/2 inhibition has been previously linked to n-3 PUFAs anti-
cancer action (17,19,20). We investigated the ERK1/2 phosphoryla-
tion in the non-neoplastic immortal oral keratinocyte line OKF6/
TERT-1 and two SCC lines, SCC-13 and SCC-25, from the epider-
mis and oral cavity, respectively. Figure 3b shows that interestingly 
within 2 h of the addition of 3 and 5 µM EPA and DHA, increased 
ERK1/2 phosphorylation is detectable in SCC-13 and SCC-25 but 
not in OKF6/TERT-1. In fact, ERK1/2 phosphorylation declined in 
n-3 PUFA-treated OKF6/TERT-1 cells, especially at the 5 µM dose 
in parallel with the effect of the lipids on growth (Figure 1a–d) and 
with the decrease of activated EGFR (Figure 3a). We did not detect 
increased endogenous ERK1/2 phosphorylation in SCCs, relative to 
their immortal but non-neoplastic counterpart. These results show 
that n-3 PUFAs affect ERK1/2 signalling differently in normal and 
malignant keratinocytes, suggesting that increased and sustained 
ERK1/2 phosphorylation may have a role in the selective inhibition 
of SCC growth by these lipids.
Figure  3c shows that within 5 h, 10 µM of both n-3 PUFAs 
leads to a significantly high activation of ERK1/2 in SCC-25 cells 
that was sustained for at least 24 h, and in other experiments, this 
increase in phosphorylation was detectable within 30 min (data not 
shown). SCC-25 cells overexpress EGFR by 10-fold and sustained 
activation of the MEK pathway has been implicated in the growth 
arrest and differentiation in neuronal cells overexpressing EGFR 
(40), whereas transient activation is usually associated with prolif-
eration. As PI3 kinase has been implicated in both protecting cells 
against apoptosis (41,42) and senescence (a form of permanent cell 
cycle arrest) (43), we tested for any alterations of the levels of phos-
phorylation of the downstream target of PI3 kinase, Akt, follow-
ing n-3 PUFA treatment. Figure 3d shows that the levels of p-AKT 
do not change significantly, which is consistent with a sustained 
ERK1/2 activation inducing apoptosis or growth arrest rather than 
proliferation.
Fig. 3. Effect of n-3 PUFAs on EGFR, ERK1/2 and Akt phosphorylation. (a) Western blots showing the activation (phosphorylation) of EGFR in SCC-25, but 
not in OKF6/TERT1 (OKF6), by DHA and EPA and also the higher constitutive levels of EGFR in SCC-25. The loading control (tubulin) is shown in the lower 
panel. Additionally, the overexposed blot shows the big difference between the activated EGFR in SCC-25 and OKF6 and also the decrease of EGFR activation 
after treatment with DHA and EPA. (b) Western blots showing increased phosphorylation of ERK1/2 (top panel) relative to total ERK1/2 (middle panel) in both 
SCC-13 and SCC-25, but not in OKF6, after the addition of 3 and 5 µM of both n-3 PUFAs for 2 h. In fact, ERK1/2 phosphorylation was reduced in OKF6 at 5 
µM. The loading control  (GAPDH) is shown in the bottom panel. (c) Western blots showing the sustained induction of ERK1/2 phosphorylation (top panel) by 
10 µM DHA and EPA after 5, 17 and 24 h compared with total ERK1/2 (middle panel) and GAPDH (bottom panel). (d) Western blot showing an absence of any 
notable change in Akt phosphorylation (top panel) by the same doses of DHA and EPA after 5 and 17 h compared with total Akt (middle panel) and GAPDH 
(bottom panel). Representative blots and densitometry of at least three or more independent experiments (for the quantification of the results) are shown. The 
levels of the phosphorylated proteins after treatment with DHA and EPA are normalized with the total protein and expressed as relative values compared with 
the protein levels of the vehicle control. Significantly different from the mean value of the untreated vehicle controls (*P < 0.05; **P < 0.01; ***P < 0.001 as 
measured by one-way ANOVA followed by post hoc Bonferroni test).
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ERK1/2 phosphorylation by n-3 PUFAs requires activation of 
EGFR but not the caspases
As SCC-25 cells are known to possess a high density of EGFR on 
their cell surface, we used this line to investigate the mechanisms 
of n-3 PUFAs action further. Figure 4 shows that the EGFR kinase 
inhibitor, AG1478, and the MEK inhibitor, AZD6244 (Figure 4a and 
b), both inhibited the phosphorylation of ERK1/2 induced by both 
DHA and EPA in SCC-25 cells. To test whether occupancy of the 
EGFR was required for activation of ERK1/2, we treated SCC-25 
cells with an EGFR-blocking antibody and showed that this was 
indeed the case at both doses 1 and 10 µg/ml, which also inhibited 
the phosphorylation of the ERK1/2 target p90 ribosomal S6 kinases 
(p90RSK) (Figure 4a and c). The effect of AZD6244 on n-3 PUFA-
induced ERK1/2 phosphorylation seems much less than that of 
the EGFR inhibitors (Figure  4a and b). However, this is probably 
because (at least partly) it had a clear effect on the endogenous levels 
of ERK1/2 phosphorylation in the controls (Figure  4d). However, 
there is still the possibility that pathways other than MEK may 
mediate the activation of ERK1/2 by n-3 PUFAs. Taken together, our 
results suggest that the n-3 PUFAs amplify EGFR signalling through 
a sustained activation of the ERK/RSK pathway to cause apoptosis 
and growth inhibition in SCC-25 cells. As many SCCs have 5–10 
times more EGFR than their normal counterparts (44), this could 
explain the selective effect of n-3 PUFAs on neoplastic keratinocytes.
It has been reported that ERK1/2 phosphorylation can be a sur-
vival mechanism so the consequence (rather than the cause) of apop-
tosis (45,46). Although the cleavage of caspases 3, 8 and 9 was much 
slower than the rapid phosphorylation of ERK1/2, we tested the 
hypothesis further by treating SCC-25 cells with both n-3 PUFAs and 
the pan-caspase inhibitor Q-VD-Oph (Figure 4e and f) and found no 
evidence for a reduction in n-3 PUFA-induced ERK1/2 phosphoryla-
tion, contrary to the results with AG1478. Therefore, we conclude that 
ERK1/2 phosphorylation induced by n-3 PUFAs is not a consequence 
of apoptosis.
EGFR occupancy is required for growth inhibition by EPA
To test whether the increased ERK1/2 phosphorylation was essential 
for the growth inhibitory effect of n-3 PUFAs we examined whether the 
EGFR neutralizing antibody could antagonize the growth inhibitory 
effect of EPA and DHA in SCC-25 cells using the MTT assay. The 
results showed that the growth inhibitory effect of EPA (Figure  5a 
and b), but not DHA (data not shown), was partially reversed by 
the inclusion of the EGFR-blocking antibody, which inhibits n-3 
PUFA-induced ERK1/2 phosphorylation (Figure  4a), from 12% of 
the ethanol control levels in the isotype control to around 40%. The 
results support the hypothesis the increased ERK1/2 activation by 
EPA is partially responsible for the growth inhibition of SCC-25 and 
Fig. 4. The inhibition of ERK1/2 phosphorylation and function by EGFR and MEK antagonists. (a) Western blots showing the effect of the indicated 
antagonists on ERK1/2 phosphorylation and its downstream target P-p90RSK as induced by 3 µM DHA and EPA in addition to the ethanol control (CON) 
2 h after treatment. Total ERK1/2 and RSK1/2/3 as well as GAPDH served as loading controls. The EGFR neutralizing antibody (EGFR-Ab) was used 
at 1 and 10 µg/ml; the EGFR kinase inhibitor AG1478 was used at 100 nM and 1 µM; and the MEK inhibitor AZD6244 was used at 100 and 300 nM. (e) 
Western blot comparing the effect of AG1478 with the pan-caspase inhibitor Q-VD-Oph on ERK1/2 as induced by 5 µM DHA and EPA in addition to the 
ethanol vehicle control 2 h after treatment. The blots are typical of three independent experiments. The graphs show the relative to the control mean value 
of P-ERK/total ERK (b and f) and P-p90RSK/total RSK (c), and they represent the mean values of three or more western blots measured by densitometry. 
(d) The graph shows the relative mean values of the n-3 PUFA- and AZD6244-treated cells compared with the untreated vehicle control. Significantly 
different from the mean value of the untreated vehicle control (*P < 0.05; **P < 0.01; ***P < 0.001 as measured by one-way ANOVA followed by post hoc 
Bonferroni test).
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that occupancy of EGFR is required for this effect (Figure 5c). The 
lack of an effect of the EGFR antibody on DHA-treated cells suggests 
that DHA activates growth inhibitory pathways in addition to those 
activated by EPA (see below).
ROS generation, oxidative damage and JNK phosphorylation by 
n-3 PUFAs at high doses may explain the weaker selective effect of 
DHA compared with EPA
DHA is just as specific as EPA in inducing ERK1/2 phosphorylation 
in SCC keratinocytes relative to their normal counterparts, yet is much 
less specific at inhibiting their growth, especially at 5 µM, where it has 
a considerable effect on normal keratinocytes (Figure 1). As n-3 PUFAs 
have been reported to induce the production of ROS and phosphorylate 
JNK at higher doses (19,30), we hypothesized that DHA might gener-
ate more ROS than EPA and, as a result, have a greater effect on nor-
mal or non-neoplastic-immortal keratinocytes. Figure 6 shows that both 
DHA and EPA cause oxidative stress in SCC-25 cells at doses of 5 µM 
and above as assessed by the fluorescence of DCF followed by fluores-
cence-activated cell sorting analysis (Figure 6a), dihydroethidium stain-
ing (data not shown) and the presence of 8-oxo-dG staining of the cell 
nuclei (Supplementary Figure  2, available at Carcinogenesis Online). 
However, EPA was less effective than DHA at inducing ROS at both 3 
and 5 µM (Figure 6a), and DHA showed much more 8-oxo-dG staining 
at 3 µM than EPA (Supplementary Figure 2, available at Carcinogenesis 
Online) and more phosphorylation of JNK at 5–10 µM in SCC-25 cells 
(Figure 6c). There was lower ROS produced at the more selective dose 
of 3 µM that had a minimal growth inhibitory effect on normal keratino-
cytes (Figure 1). When ROS was measured in the normal keratinocytes 
NHEK-131 and OKF6/TERT-1, both n-3 PUFAs still produced ROS but 
less compared with SCC-25. However, the increase in ROS was statisti-
cally significant only at the dose of 5 µM.
As both EPA and DHA were shown to elicit oxidative damage 
and activate JNK in SCC-25 cells at doses of 5–10 µM (Figure  6; 
Supplementary Figure  2, available at Carcinogenesis Online), we 
tested whether the antioxidants PBN and α-tocopherol (data not 
shown) could reverse the growth inhibitory effects of DHA and EPA at 
doses of 3–10 µM, but this was not the case (Supplementary Figure 3, 
available at Carcinogenesis Online), suggesting that the induction of 
ROS is not the only cause of the n-3 PUFA-induced growth inhibition 
but may compromise its specificity.
Discussion
Many previous studies support the hypothesis that n-3 PUFAs can inhibit 
the formation and progression of cancers (5,9,11,12,14), and other 
studies have highlighted their role in augmenting therapeutic strategies 
Fig. 5. The EGFR neutralizing antibody partially rescues EPA growth inhibitory effect. (a) MTT viability assay showing the extent of the growth inhibition by 
EPA with and without two doses of the EGFR neutralizing antibody that had previously been shown to block ERK1/2 phosphorylation by EPA. The control was 
an isotype-matched antibody. The results are the means of four independent experiments ± SEM. (b) Graph showing the same data expressed relative to the effect 
of EPA on growth in the presence of the isotype control antibody. *P < 0.05. (c) Schematic representation of our model is shown. The occupancy of EGFR by 
ligands such as transforming growth factor-α is hypothesized to be important to the inhibition of proliferation and the induction of apoptosis by EPA, based on 
the effects of the EGFR-blocking antibody (a)and (b). The diagram summarizes the hypothesis that EPA selectively inhibits the growth of human SCC cells by 
inducing a sustained activation of ERK1/2 (solid arrows) to inhibit proliferation and induce apoptosis, whilst having the opposite (or no) effect on normal cells, 
which normally respond to EGFR occupancy with transient and reduced ERK activation (hatched arrow).
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(14). However, although it is acknowledged that n-3 PUFAs may act on 
the cancer microenvironment for example, by inhibiting inflammation 
(47), the mechanism of action of this important class of lipids in tumour 
suppression is incompletely understood. In particular, EPA, but not its 
metabolite DHA, has been reported to inhibit the promotion phase of 
epidermal SCC development (9), rendering it a strong candidate for a 
chemopreventive agent of epidermal and aerodigestive tract SCC, where 
field cancerization is a major clinical problem (3,4). Furthermore, the 
accessibility of much of the aerodigestive tract and the epidermis to 
aerosols or gels would help deliver higher local doses.
We show here that EPA is much more selective in the growth inhi-
bition of premalignant human oral keratinocytes than DHA, although 
both showed some selectivity against SCC cells. The growth inhibi-
tory effect was a combination of inhibited proliferation and the induc-
tion of apoptosis, in agreement with Schley et al. (18), via both the 
intrinsic (caspase 9) and extrinsic pathways (caspase 8).
Interestingly, in our study, the inhibition of keratinocyte growth was 
associated with a rapid and sustained phosphorylation of ERK1/2 in 
neoplastic cell lines. The phosphorylation of ERK1/2 and partially, the 
growth inhibitory effect of EPA, were dependent on the occupancy and 
activation of EGFR. ERK1/2 phosphorylation was not accompanied by a 
concomitant phosphorylation of AKT indicative of increased PI3 kinase 
activity. This is not surprising as EGFR has been reported to enhance 
ERK phosphorylation downstream of MEK through dual-specificity 
phosphatases (48) but could result in a signalling imbalance that has pre-
viously been shown to trigger apoptosis (41,42) or senescence (43). The 
phosphorylation of ERK1/2 and its downstream target p90RSK, by both 
EPA and DHA, was antagonized by the EGFR-blocking antibody (mAb 
225), the EGFR kinase inhibitor AG1478 but to a lesser extent by the 
MEK inhibitors, U0126 (data not shown) and AZD6244, which supports 
the hypothesis that ERK1/2 phosphorylation might also be increased by 
pathways other than MEK (48).
Activation of the ERK1/2 pathway was not inhibited by a pan-cas-
pase inhibitor, we were able to partially rescue the growth inhibitory 
effects of EPA with an EGFR-blocking antibody, and the phospho-
rylation of ERK1/2 following EPA treatment occurred within 30 min, 
whereas caspase activation, as determined by the cleavage of caspase 
3, took over 5 h. Therefore, the phosphorylation of ERK1/2 was not 
just a survival mechanism and a consequence of apoptosis as reported 
in certain settings (45,46).
Even though the activation of ERK is traditionally linked to cell 
survival and proliferation (24), several recent studies show that 
Fig. 6. Effect of n-3 PUFAs on ROS levels and JNK phosphorylation in SCC-25 cells. (a) A DCF fluorescence-activated cell sorting assay showing the effect of 
3 and 5 µM EPA and DHA on the ROS levels in SCC-25 cancer cells together with OKF6/TERT-1 (OKF6) and NHEK-131 (NHEK) normal keratinocytes. The 
results are expressed as percentages of each vehicle control. Human fetal skin fibroblasts with low ROS production served as a negative control and tert-butyl 
hydroperoxide-treated SCC-25 (TBHP) cells as a positive control and were expressed as a percentage of the SCC-25 untreated control. (b) Representative picture 
of DCF positively stained cells showing DCF staining (upper panel), nuclear staining with Hoechst 33258 (central panel) and an overlay of the two (bottom 
panel). (c) Representative western blot showing the effect of DHA and EPA at 5 and 10 µM after 2 h on JNK phosphorylation, showing an increase at both 5 and 
10 µM with DHA appearing more potent than EPA. The graph summarizes the results of three western blots measured by densitometry. The results are the means 
of three experiments ± SEM. Significantly different from the mean value of the untreated vehicle controls (*P < 0.05; **P < 0.01; ***P < 0.001 as measured by 
one-way ANOVA followed by post hoc Bonferroni test).
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activation of ERK could actually cause apoptosis or cycle arrest (25–
28). Wang et  al. (49) showed that cisplatin-induced apoptosis was 
dependent on MEK/ERK signalling and Elder et al. (25) demonstrated 
that sustained ERK1/2 activation mediates apoptosis induction by the 
nonsteroidal anti-inflammatory drug NS-398 in colon cancer cells. So 
ERK activation effect is not as straightforward as previously thought, 
and it depends on the type, strength and duration of the stimulus and on 
the cell type (25). Therefore, an increase in ERK1/2 phosphorylation 
upstream of apoptosis is not without precedent.
Our data are consistent with the inhibition of cell growth by a 
sustained activation of ERK1/2 (40), whereas the inhibition of SCC 
growth by inducing a sustained activation of EGFR has been also 
previously reported (50). The selective inhibition of growth seen in 
neoplastic keratinocytes could be explained by the higher density of 
EGFR in these cells (44) (Figure 5c).
Some previous studies have linked the n-3 PUFA tumour-sup-
pressive action with the mitogen-activated protein kinase pathway, 
although showed that n-3 PUFAs, especially DHA, can promote 
apoptosis by inhibiting ERK1/2 phosphorylation (17,19,20). The 
fat-1 mouse shows slightly lower levels of MEK and ERK1/2 phos-
phorylation in normal breast tissue compared with the wild-type 
(17), similar to our observations on a non-neoplastic keratinocyte 
line. However, the status of ERK1/2 phosphorylation was not exam-
ined in fat-1 mouse breast tumours and so this report (17) does not 
conflict with our new observations. Notably, and consistent with our 
study, another group has reported that both DHA and EPA can cause 
a decrease in EGFR levels in lipid rafts isolated from a human breast 
cancer line and that this was associated with an increase in EGFR 
(16) and also with apoptosis (18). However, in these studies, no link 
between increased EGFR and ERK1/2 phosphorylation, which leads 
to growth inhibition and apoptosis, was established, and no compari-
son with normal cells was made.
Although both n-3 PUFAs induced a rapid phosphorylation of ERK1/2 
and its downstream target p90RSK, DHA produced rather more ROS 
and phosphorylated JNK than EPA in SCC-25, and this might explain 
why the EGFR-blocking antibody failed to rescue its growth inhibitory 
effects. Both n-3 PUFAs produced ROS in normal cells, which is 
statistically significant at the higher doses but generally less compared 
with SCC-25. A  possible explanation is that they bear protective 
mechanisms against ROS, which might be lost in cancer cells and p53, 
dysfunctional in most of the neoplastic cells in this study, is known to 
orchestrate an antioxidant response (51). Taken together, these support 
the hypothesis that the generation of ROS might be one reason why some 
of the normal cells are dying, especially at high doses of PUFAs, and this 
might compromise their selective growth inhibition towards neoplastic 
keratinocytes. As DHA is synthesized from EPA, albeit inefficiently in 
humans (52), our data suggest that modifying EPA, so that it produces 
less DHA might reduce the formers toxicity to normal cells; this could 
also be achieved by inhibiting an essential enzyme, such as Δ6-desaturase 
(52). Even though both n-3 PUFAs generated ROS at the higher doses, 
caused oxidative damage and activated JNK, ROS generation was not 
the only mechanism of growth inhibition at these doses because the cells 
could not be rescued by antioxidants. However, the effects of EPA could 
be rescued by blocking the EGFR, albeit not completely, suggesting 
that several mechanisms including ROS induction may contribute to n-3 
PUFAs growth inhibition of SCC-25 cells.
In conclusion, we have shown that n-3 PUFAs, and especially 
EPA, have a selective growth inhibitory effect on neoplastic human 
keratinocytes, causing both reduced proliferation and apoptosis (intrinsic 
and extrinsic pathway), and that this effect is partially mediated by 
activation of the ERK1/2 pathway through EGFR, demonstrated here 
for the first time. The results suggest that EPA should be considered 
as a chemopreventive agent for SCC, both in the context of preventing 
tumour recurrence from a cancerous field or its formation in risk groups 
such as former smokers. The identification of ERK1/2 phosphorylation 
as an important event in SCC growth inhibition identifies it as a potential 
biomarker for n-3 PUFAs action in vivo but may also be informative in 
the identification or development of n-3 PUFAs that are more effective 
chemopreventive agents than EPA.
Finally, drugs that inhibit the EGFR such as cetuximab are 
currently undergoing phase II trials for the locoregional control of 
head and neck SCC (53), and n-3 PUFA supplements are often given 
to such patients post-operatively (54). Therefore, our results showing 
a potential antagonism between n-3 PUFAs and EGFR antagonists 
suggest that such trials should take this into account.
Supplementary material
Supplementary Figures 1–3 can be found at http://carcin.oxfordjour-
nals.org/
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